S Schreiber1, O Bachmann. 1. Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Christian-Albrechts-Universität zu Kiel, Schittenhelmstr. 12, 24105, Kiel, Deutschland, s.schreiber@mucosa.de.
Abstract
BACKGROUND: The therapeutic options for chronic inflammatory bowel diseases have seen an enormous development over the last decades. However, there are several unmet needs which warrant the development of additional biologics for a better and complete control of the inflammatory process. STATE OF DEVELOPMENT: Novel biological therapies that will be approved in the near future include blockade of the adhesion molecule integrin alpha4beta7 and the cytokine interleukin 23. Large phase III trials have established the clinical efficacy in ulcerative colitis and Crohn's disease, respectively. The development of biologic therapies in earlier stages includes additional antibodies that block adhesion molecules as well as biologics that intercept the interleukin 6 pathway. CONCLUSION: The therapeutic landscape in inflammatory bowel disease will be enriched by additional biologic therapies. Clinical studies should investigate the interaction with existing therapies, e.g. anti-tumor necrosis factor (TNF) therapies and the development of new endpoints for a better disease control and for improved long-term outcome.
BACKGROUND: The therapeutic options for chronic inflammatory bowel diseases have seen an enormous development over the last decades. However, there are several unmet needs which warrant the development of additional biologics for a better and complete control of the inflammatory process. STATE OF DEVELOPMENT: Novel biological therapies that will be approved in the near future include blockade of the adhesion molecule integrin alpha4beta7 and the cytokine interleukin 23. Large phase III trials have established the clinical efficacy in ulcerative colitis and Crohn's disease, respectively. The development of biologic therapies in earlier stages includes additional antibodies that block adhesion molecules as well as biologics that intercept the interleukin 6 pathway. CONCLUSION: The therapeutic landscape in inflammatory bowel disease will be enriched by additional biologic therapies. Clinical studies should investigate the interaction with existing therapies, e.g. anti-tumor necrosis factor (TNF) therapies and the development of new endpoints for a better disease control and for improved long-term outcome.
Authors: Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis Journal: Gut Date: 2012-05-17 Impact factor: 23.059
Authors: Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts Journal: N Engl J Med Date: 2005-06-09 Impact factor: 91.245
Authors: Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho Journal: Science Date: 2006-10-26 Impact factor: 47.728
Authors: Bruce Yacyshyn; William Y Chey; Mark K Wedel; Rosie Z Yu; David Paul; Emil Chuang Journal: Clin Gastroenterol Hepatol Date: 2007-02 Impact factor: 11.382
Authors: William J Sandborn; Jean-Frederic Colombel; Bruce E Sands; Paul Rutgeerts; Stephan R Targan; Remo Panaccione; Brian Bressler; Karl Geboes; Stefan Schreiber; Richard Aranda; Sheila Gujrathi; Allison Luo; Yun Peng; Luisa Salter-Cid; Stephen B Hanauer Journal: Gastroenterology Date: 2012-04-12 Impact factor: 22.682
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245